The study supports HPRT1 as a key driver of chemoresistance and tumor progression in OSCC, operating through MMP1‐mediated PI3K/AKT activation, and highlights its potential as a therapeutic vulnerability. This evidence concerns the gene PIK3CB and neoplasm.